Royalty Pharma
RPRX
395 hedge funds and large institutions have $8.86B invested in Royalty Pharma in 2024 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 159 increasing their positions, 123 reducing their positions, and 39 closing their positions.
1,323% more call options, than puts
Call options by funds: $20.8M | Put options by funds: $1.47M
51% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 39
29% more repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 123
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
6% more capital invested
Capital invested by funds: $8.35B → $8.86B (+$508M)
4% more funds holding
Funds holding: 378 → 395 (+17)
0.21% less ownership
Funds ownership: 70.09% → 69.88% (-0.21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$55.2M |
| 2 |
Amundi
Paris,
France
|
+$45.1M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$37.7M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$30.6M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$26.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$179M |
| 2 |
UE
Unisphere Establishment
Vaduz,
Liechtenstein
|
-$132M |
| 3 |
Morgan Stanley
New York
|
-$84.6M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$30M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$28.2M |
RPRX Hedge Fund Activity: Q3 2024 in Review
395 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2024, worth a combined $8.86B — up 6.1% from $8.35B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new RPRX positions and 39 closed out — a net gain of 20 holders — while 159 added to existing stakes and 123 trimmed.
The largest buyer was Millennium Management, adding an estimated $55.2M. The largest seller was JP Morgan Chase, cutting an estimated $179M.
- 395 institutional investors held Royalty Pharma (RPRX) as of Q3 2024, up from 378 in Q2 2024.
- Funds reported $8.86B of Royalty Pharma stock for Q3 2024, up 6.1% quarter-over-quarter.
- 59 funds opened new Royalty Pharma positions in Q3 2024 and 39 closed out, a net change of +20 holders.
- The largest Royalty Pharma buyer in Q3 2024 was Millennium Management, an estimated $55.2M added.
- The largest Royalty Pharma seller in Q3 2024 was JP Morgan Chase, an estimated $179M sold.
Based on aggregated 13F filings for Q3 2024.